Literature DB >> 8507759

Open, randomized therapeutic trial of six antimicrobial regimens in the treatment of human brucellosis.

J M Montejo1, I Alberola, P Glez-Zarate, A Alvarez, J Alonso, A Canovas, C Aguirre.   

Abstract

This report describes the results of six antimicrobial regimens used for the treatment of brucellosis in an open, randomized study performed over two periods (1980-1983 and 1984-1987). In the first period, rifampicin and doxycycline were used for 4 weeks, trimethoprim-sulfamethoxazole for 6 months, and doxycycline for 6 weeks. During the second period, we used streptomycin for 2 or 3 weeks together with doxycycline for 6 weeks and rifampicin with doxycycline for 6 weeks. Comparison of the results showed the following: (1) no statistically significant findings were revealed when the different regimens were compared and (2) the regimens containing streptomycin yielded statistically more favorable results than those consisting of rifampicin and monotherapy when the patients treated with rifampicin were compared with those taking streptomycin and those receiving single-agent therapy. No significant differences were observed between monotherapeutic regimens and those including rifampicin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8507759     DOI: 10.1093/clind/16.5.671

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  16 in total

1.  Increasing resistance of Brucellae to co-trimoxazole.

Authors:  A Kinsara; A Al-Mowallad; A O Osoba
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

2.  Hydrophobic gentamicin-loaded nanoparticles are effective against Brucella melitensis infection in mice.

Authors:  Edurne Imbuluzqueta; Carlos Gamazo; Hugo Lana; Miguel Ángel Campanero; David Salas; Ana Gloria Gil; Elisa Elizondo; Nora Ventosa; Jaume Veciana; María J Blanco-Prieto
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

3.  Brucella endocarditis - a series of five case reports.

Authors:  I Tammi Raju; Rachana Solanki; A N Patnaik; R C Barik; N R Kumari; A S Gulati
Journal:  Indian Heart J       Date:  2013-01-02

4.  Survey of Omp19 immunogenicity against Brucella abortus and Brucella melitensis: influence of nanoparticulation versus traditional immunization.

Authors:  Morteza Abkar; Abbas Sahebghadam Lotfi; Jafar Amani; Khadijeh Eskandari; Mehdi Fasihi Ramandi; Jafar Salimian; Gholamreza Nikbakht Brujeni; Saeed Alamian; Mehdi Kamali; Hamid Koushki
Journal:  Vet Res Commun       Date:  2015-09-22       Impact factor: 2.459

5.  Broth microdilution susceptibility testing of Brucella species: quality control limits for ten antimicrobial agents against three standard quality control strains.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

6.  Treatment of human brucellosis with doxycycline and gentamicin.

Authors:  J Solera; A Espinosa; E Martínez-Alfaro; L Sánchez; P Geijo; E Navarro; J Escribano; J A Fernández
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

Review 7.  Recognition and optimum treatment of brucellosis.

Authors:  J Solera; E Martínez-Alfaro; A Espinosa
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

8.  A sporadic outbreak of human brucellosis in Korea.

Authors:  Mi-Yeoun Park; Chang-Seop Lee; Young-Sil Choi; Seoung-Ju Park; Joo-Sun Lee; Heung-Bum Lee
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

9.  Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas.

Authors:  J Solera; M Rodríguez-Zapata; P Geijo; J Largo; J Paulino; L Sáez; E Martínez-Alfaro; L Sánchez; M A Sepulveda; M D Ruiz-Ribó
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

Review 10.  Genital manifestations of tropical diseases.

Authors:  J Richens
Journal:  Sex Transm Infect       Date:  2004-02       Impact factor: 3.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.